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Abstract: Since methamphetamine (MAP) has been frequently inhaled simultaneously with nicotine, i.e., cigarette 
smoking mixed with MAP, the modification by nicotine of the behavioral sensitization to MAP was evaluated in terms of 
ambulatory activity in mice.  During the 5 repeated co-administrations of MAP (2 mg/kg s.c.) with nicotine (0.03, 0.1, 0.3 
and 1 mg/kg s.c.) at 3 day intervals, nicotine dose-dependently inhibited the progressive enhancement of MAP-induced 
ambulatory stimulation.   However, such pre-treatments did not modify the induction of ambulatory sensitization to MAP 
(2 mg/kg s.c.).  In both the drug-naive and MAP-sensitized mice, nicotine reduced the ambulatory stimulant effect of MAP. 
These results suggest that, although nicotine reduces the expression of ambulatory stimulant effect of MAP, nicotine does 
not protect, but rather accelerate, the induction of psychotoxic effect of MAP.
(Reprint request should be sent to Hisashi Kuribara)
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Introduction
Methamphetamine (MAP) abuse is the most serious 
drug abuse problem in Japan. Although MAP has tradition-
ally been administered through intravenous route, an inha-
lation of MAP vapor, namely ABURI, or smoking MAP 
mixed with tobacco, namely MOKU, is increasing not only 
because to avoid infections and the trace of picking needle, 
but also because of easy way for taking the drug.
The central stimulant effect of amphetamines is caused 
by an acceleration of dopamine release from the cytoplas-
mic pool of neurons at nucleus accumbens and striatum 
(McMillen, 1873). It has been known that the repeated 
administration of MAP induces the sensitization to its 
behavioral stimulant effect in animals (Tadokoro and 
Kuribara, 1986) and causes the increased risk of psycho-
toxic symptoms such as delusion and hallucination in 
humans (Wise and Bozarth, 1987).
Nicotine, an agonist of nicotinic acetylcholine receptors 
(Fuxe et al., 1986; Imperato et al., 1986; Marks et al., 
1986), also accelerates dopamine release in the brain 
(Marks et al., 1986; Sershen et al., 1991; Jutkiewicz et al., 
2008), and shows an ambulatory stimulant effect in 
rodents, particularly in rats (Kita et al., 1992; Ann-Sophie 
et al., 2006). Such neurochemical and behavioral charac-
teristics of nicotine are partially similar to those of amphet-
amines. However, there are some reports which suggest an 
antagonistic effect of nicotine on the amphetamine-induced 
ambulatory stimulation and stereotyped behaviors (Stevens 
et al., 1995), and impairment of auditory sensory gating 
(Stevens et al., 1995).
Since MAP is inhaled simultaneously with nicotine fol-
lowing the smoking MAP mixed with tobacco, it is important 
to behaviorally assess the combined effect of MAP and 
nicotine, although the combined effects of nicotine and 
N-cyanomethylmethamphetamine, a main pyrolysis product 
of smoking methamphetamine mixed with tobacco, have 
been reported (Sekine et al., 1997; Kuribara, 2010).
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The aim of the present study was to evaluate the modifi-
cation by nicotine of the induction and expression of 
behavioral sensitization to MAP in mice. The following two 
experiments were conducted: 1) Repeated co-administra-
tions of MAP with nicotine, and followed by the challenge 
administration of MAP alone. 2) The induction of MAP-
sensitization and followed by co-administration of MAP 
with nicotine. 3) Repeated administration of nicotine and 
was followed by the challenge administration of MAP.
Materials and Methods
 Animals
Male mice of ddY strain (Japan Laboratory Animals, 
Tokyo) were used at the age of 6 weeks (weighing 25-30 g). 
These mice were housed in groups of 10 in polycarbonate 
cages (20W X 25L X 10H cm) in a controlled room (tem-
perature; 23 ± 2 ℃ , relative humidity; 55 ± 3 %, and 
light on between 05:00-19:00 hr). They could eat a solid 
diet (MF: Oriental Yeast, Tokyo) and drink tap water 
except during the behavioral tests.
Apparatus
The ambulatory activity of 10 mice was individually and 
simultaneously measured with a tilting-type “ambulometer” 
(SMA-10: O’hara & Co., Tokyo). This apparatus has 10 
bucket-like activity cages of 20 cm in diameter and 15 cm 
in height. Each slight tilt of the activity cage generated by 
a horizontal movement (ambulation), but not by any vertical 
movements or turning, of the mouse was detected with one 
of 3 microswitches attached to the activity cage. 
Drugs
The drugs used were methamphetamine HCl (MAP: 
Phylopone; Dainippon Pharm., Osaka) and nicotine free 
base (Nakarai Chemical., Tokyo). MAP and nicotine were 
dissolved in physiological saline, and the concentration of 
each drug solution was adjusted so that the volume injected 
(s.c.) was always constant at 0.1 ml/10 g body weight of 
the mouse. The dose of MAP was fixed to 2 mg/kg in the 
salt form which was optimum for increasing the ambula-
tion without producing any strong stereotyped behaviors 
throughout the 5 repeated administrations at 3-day intervals 
in the ddY strain mice (Kuribara and Hirabayashi, 1985; 
Kuribara et al., 1996a, b).
Experimental schedules
Prior to the drug administration, mice were adapted to 
the activity cage for 10 min. After the drug administration, 
the ambulatory activity of each mouse was measured for 
3 hr. All the behavioral tests were carried out between 
09:00-16:00 hr.
Experiment 1. Repeated co-administrations of MAP with 
nicotine, and then challenge administration of MAP alone
Five groups of mice (10 each) were first treated with 5 
repeated administrations of either MAP alone (nicotine 
dose=0) or MAP in combination with nicotine (0.03, 0.1, 
0.3 or 1 mg/kg) at 3-day intervals. Three days after the 5th 
treatment, all mice were challenge-administered with MAP 
alone. In addition, the administration of MAP to the drug-
naive mice (n=10) that were age-matched to the mice 
treated with the co-administrations of MAP with nicotine 
was also conducted.
Experiment 2. Induction of MAP-sensitization and then 
challenge administration of MAP in combination with nicotine
To induce the sensitization to MAP, 5 groups of mice 
(10 each) were first treated with 5 repeated administrations 
of MAP at 3-day intervals in the same way as in experi-
ment 1. Three days after the 5th treatment, all groups of 
mice were challenged with either MAP alone (nicotine 
dose=0), or combination of MAP with nicotine (0.03, 0.1, 
0.3 or 1 mg/kg).
Experiment 3. Repeated administrations of nicotine and 
then challenge administration of MAP alone, or MAP in 
combination with nicotine
Two set of 2 groups of mice (10 each) were administered 
saline (nicotine dose=0), or nicotine (1 mg/kg s.c.) once a 
day for 10 days in their home cages. These drug treatments 
were not followed by the measurement of ambulatory activ-
ities of mice. The days after the 10th treatment, 2 groups of 
mice of the first and second set were challenge-administered 
with MAP alone and MAP with nicotine (1 mg/kg).
Ethical consideration for experimental animals
All the experimental treatments of mice mentioned above 
were carried out according to the “Guiding Principles for 
the Care and Use of Laboratory Animals” of The Japanese 
Pharmacological Society.
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Statistical analysis
Mean 3-hr overall ambulatory activity counts after the 
drug administrations were first analyzed by one- or two-
way analysis of variance. In cases of significant variance, 
post-hoc analyses were carried out by Bonferoni test. 
Values of p less than 0.05 were considered significant.
Results
Experiment 1. Repeated co-administrations of MAP 
with nicotine, and then challenge administration of 
MAP alone
As shown in Table 1, the repeated co-administrations of 
MAP with nicotine induced a progressive enhancement of 
the ambulatory stimulant effect in all groups of mice. 
Nicotine reduced the stimulant effect of MAP in a dose-
dependent manner in the repeated administration phase.
However, following the challenge administration of 
MAP, there was no significant difference in the activity 
counts among the groups of mice that had been treated 
with MAP alone or combination of MAP with nicotine.
Experiment 2. Combined administration of MAP with 
nicotine to the MAP-sensitized mice
Five repeated administrations of MAP (2mg/kg s.c.) at 
3-day intervals resulted in an sensitization to the ambulatory 
stimulant effect of MAP in all groups of mice; the activity 
counts at the 1st and 5th administration being 1500-1600 
and 5000-5200, respectively (data are not shown). 
Table 2 shows mean 3-hr activity counts after the 
administration of MAP alone (nicotine dose=0) or MAP in 
combination with nicotine (0.03-1 mg/kg) to the MAP-
Table 1.   Mean 3-hr ambulatory activity counts ± SEMs after 5 repeated administrations of methamphetamine  
(MAP: 2 mg/kg s.c.) alone, and MAP with nicotine (NICO: 0.03, 0.1, 0.3 and 1 mg/kg s.c.)  
at 3-day intervals, and the challenge administration of MAP.
Doses of drugs 1st 2nd 3rd 4th 5th MAP-challenge
MAP only 1595 ±  220 2206 ±  311 4189 ±  593* 4630 ±  651* 4772 ±  707* 5001 ±  617#
MAP+NICO (0.03) 1570 ±  238 2122 ±  274 3620 ±  582* 4747 ±  630* 4699 ±  650* 5199 ±  630#
MAP+NICO(0.1) 1278 ±  194 1807 ±  239 2752 ±  374*,$ 4139 ±  511* 4254 ±  630* 5166 ±  619#
MAP+NICO(0.3) 1110 ±  121$ 1460 ±  190$ 2754 ±  410*,$ 3680 ±  517* 3535 ±  520* 5234 ±  704#
MAP+NICO(1)  912 ±  130$ 1104 ±  148$ 1906 ±  293*,$ 3005 ±  404*,$ 2918 ±  445*,$ 4906 ±  539#
MAP 1549 ±  207
*:  Significantly different vs. the count at the first administration within each group (p<0.05).  $: Significantly different from 
the count of MAP alone-treated group at the same administration number (p<0.05).  #: Significantly different from the 
count following the administration of MAP to the drug-naive mice (p<0.05). N=10 in each group.
Table 2.   Mean 3-hr ambulatory activity counts ± SEMs after the administration of methamphetamine  
(MAP: 2 mg/kg s.c.) alone, co-administration of MAP with nicotine (NICO: 0.03-1 mg/kg s.c.),  
or nicotine alone to the MAP-sensitized mice.
Doses of drugs Drug naive MAP-sensitized
MAP alone 1595 ±  220 5120 ±  656
MAP + NICO (0.03 mg/kg) 1570 ±  238 4660 ±  591
MAP + NICO (0.1 mg/kg) 1273 ±  194 3570 ±  581*
MAP + NICO (0.3 mg/kg) 1110 ±  121* 3033 ±  453*
MAP + NICO (1 mg/kg)  912 ±  130* 2605 ±  349*
*:  Significantly different from the activity count following the challenge administration of MAP (p<0.05). N=10 in each group.
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sensitized mice. For comparison, the activity counts in the 
drug-naive mice, which are shown in Table 1 (the counts at 
the 1st administration), are also presented.
The ambulatory stimulant effect of MAP was reduced 
by nicotine in both the drug-naive and MAP-sensitized 
mice. The activity counts following the co-administration 
of MAP with 0.3-1 mg/kg nicotine in the drug-naive and 
MAP-sensitized mice were significantly lower than those 
following the administration of MAP alone.
Experiment 3. Repeated administrations of nicotine 
and then challenge administration of MAP alone, or 
MAP in combination with nicotine
As shown in Table 3, the pretreatment with nicotine (1 
mg/kg s.c., 10 times) did not change the sensitivity to 
MAP or MAP + nicotine.
Discussion
In agreement with our previous reports (Kuribara and 
Hirabayashi, 1985), the repeated administrations of MAP 
induced significant sensitization to the ambulatory stimulant 
effect of MAP. The central stimulant effect of MAP is 
caused by acceleration of dopamine release from the cyto-
plasmic pool (McMillen, 1983). It is generally considered 
that the nicotine-induced behavioral stimulation is caused 
by an acceleration of dopaminergic neurotransmission 
through stimulation of acetylcholine release in the brain 
(Kita et al., 1992; Sershen et al., 1991). Amphetamine and 
nicotine interact to enhance their behavioral and neuro-
chemical effects in rats (Huston-Lyons et al., 1993; Anne-
Sophie et al., 2006).
However, it is notable that the ambulatory stimulant 
effect of MAP was significantly reduced by nicotine in 
both the drug-naive and MAP-sensitized mice. These 
results are in consistent with the inhibitory effects of nico-
tine on the amphetamine-induced locomotor stimulation 
(Stolerman et al., 1973), stereotyped behavior (Arnfred 
and Rundrup, 1968; Klawans et al., 1972), and impairment 
of auditory gating in rats (Stevens et al., 1995). Some 
mechanisms can be considered to be involved in the antag-
onistic effect of nicotine on the behavioral stimulant effect 
of amphetamines.
The possible mechanism is the nicotine-induced dopa-
mine release through a stimulation of the nicotinic acetyl-
choline receptors in the brain, which may reduce the 
amphetamine-induced dopamine release (Sershen et al., 
1991). Anne-Sophie et al. (2006) suggested a role of sero-
tonergic mechanism in the nicotine-induced locomotor 
effect in mice.
Mesolimbic dopaminergic systems (Van der Heuval and 
Pasterkamp, 2008) play significant roles not only in the 
reward effect of drugs, i.e., substance abuse liability 
(Ikemoto, 2007; Piercem and Kumaresan 2006; Berridge, 
2007), but also in the behavioral and psychological activi-
ties, particularly, motivation (Matsumoto and Hikosaka, 
2009).  Janhunen and Ahtee (2007) reported differential 
nicotinic regulation of the nigrostriatal and mesolimbic 
dopaminergic pathways. It is therefore important to assess 
the changes in the behavioral effect following the repeated 
combined administration of central stimulants including 
MAP and related drugs with nicotine.
The behavioral sensitization to amphetamines has been 
considered to be related not only to the risk of the abuse 
liability (Wise and Bozarth, 1987) but also to the risk of the 
induction of psychotoxic symptoms, namely amphetamine 
psychosis, following the repeated abuse of amphetamines 
(Tadokoro and Kuribara, 1986; Robinson and Becker, 
Table 3.   The activity counts following the challenge administration of methamphetamine 
(MAP: 2 mg/kg s.c.) to the mice pretreated with saline or nicotine (NICO: 1 mg/kg s.c.) 
daily for 10 days.
Pretreatment (10 times)
Challenge administration
MAP MAP + NICO
Saline 1552±271 891± 93*
NICO (1 mg/kg) 1598±259 922±129*
*:  Significantly different from the activity count following the challenge administration of MAP.
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1986). The present study showed that, although nicotine 
inhibited the acute ambulatory stimulant effect of MAP, 
the sensitization to MAP was not modified by nicotine. 
N-cyanomethylmethamphetamine, a main pyrolysis product 
of smoking methamphetamine mixed with tobacco, inhibited 
the behavioral stimulant effect of MAP (Sekine et al., 1997), 
but enhanced the induction of behavioral sensitization to 
MAP (Kuribara, 2010).
These results suggest that nicotine does not change the 
process of the behavioral sensitization to MAP. It is there-
fore highly probable that the repeated smoking MAP 
mixed with tobacco may not protect the liability of MAP 
abuse. This result also indicates another problem of MAP 
abuse mixed with tobacco. Thus, to recover the reward 
effect of these drugs, the combined MAP abuse mixed with 
tobacco may increase the MAP dose, and may accelerate 
the risk of the MAP-induced psychotoxic symptoms.
References
Ann-Sophie, V., Lucas, S., Gerald, B., et al. (2006): 
Irreversible blockade of monoamine oxidase reveals 
the critical role of 5-HT transmission in locomotor 
response induced by nicotine in mice. Eur. J. Neurosci. 
24, 1359-1365.
Arnfred, T. and Rundrup, A. (1968): Cholinergic mechanisms 
in brain inhibiting amphetamine-induced stereotyped 
behavior. Acta Pharmacol. Toxicol. 26, 384-394.
Fuxe, K., Andersson, K., Härstrand, A., et al. (1986): 
Increase in dopamine utilization in certain limbic 
dopamine terminal populations after a short period of 
intermittent exposure of male rats to cigarette smoke. J. 
Neural. Transm. 67, 15-29.
Huston-Lyons, D., Sarkar, M. and Kornetsky, C. (1993): 
Nicotine and brain-stimulation rewards: Interaction with 
morphine, amphetamine and pimozide. Pharmacol. 
Biochem. Behav. 46, 453-457.
Ikemoto, S. (2007): Dopamine reward circuitry: Two 
projection systems from the ventral midbrain to the 
nucleus accumbens-olfactory tubercle complex. Brain 
Res. Rev. 56, 27-78.
Imperato, M., Mulas, A. and Di Chiara, G. (1986): Nicotine 
preferentially stimulates dopamine release in the lim-
bic system of freely moving rats. Eur. J. Pharmacol. 
132, 337-338.
Janhunen. S. and Ahtee, L. (2007): Differential nicotinic 
regulation of the nigrostriatal and mesolimbic dopami-
nergic pathways: Implications for drug development. 
Neurosci. Biobehav. Rev. 31, 287-314.
Jutkiewics, E., Nicolazzo, D., Kim, M., et al. (2008): 
Nicotine and amphetamine acutely cross-potentiate 
their behavioral and neurochemical responses in 
female Holzman rats. Psychopharmacology 200, 
93-103.
Kalivas, P.W. and Stewart, J. (1991): Dopamine transmis-
sion in the initiation and expression of drug- and 
stress-induced sensitization of motor activity. Brain 
Res. Rev. 16, 223-244. 
Kita, T., Okamoto, M. and Nakashima, T. (1992): Nicotine-
induced sensitization to ambulatory stimulant effect 
produced by daily administration into the ventral 
tegmental area and the nucleus accumbens in rats. Life 
Sci. 50, 583-590.
Kuribara, H. and Hirabayashi, M. (1985): Reverse tolerance 
to psychotropic drugs. Jpn. J. Neuropsychopharmacol. 
7, 421-439.
Kuribara, H. (2010): Interaction of nicotine and N-cyano-
methylmethamphetamine, a main pyrolysis product of 
smoking methamphetamine mixed with tobacco, in 
terms of the sensitization to the ambulatory stimulant 
effect in mice. Bull. Tokyo Univ. Graduate Sch. Social 
Welfare 1: 121-129.
Marks, M.J., Miner, L.L., Cole-Harding, S., et al. (1986): 
A genetic analysis of nicotine effects on open field 
activity. Pharmacol. Biochem. Behav. 24, 743-749. 
Matsumoto, M. and Hikosaka, O. (2009): Two types of 
dopamine neuron distinctly convey positive and nega-
tive motivational signals. Nature 459, 837-841.
McMillen, B.A. (1983): CNS stimulants: Two distinct 
mechanisms of action for amphetamine-like drugs. 
Trends Pharmacol. Sci. 4, 429-432.
Piercem, R.C. and Kumaresan, V. (2006): The mesolimbic 
dopamine system: The final common pathway for the 
reinforcing effect of drugs of abuse? Neurosci. Biobehav. 
Rev. 30, 215-238.
Robinson, T.E. and Becker, J.B. (1986): Enduring changes 
in brain and behavior produced by chronic amphet-
amine administration: A review and evaluation of animal 
models of amphetamine psychosis. Brain Res. Rev. 
11, 157-198.
8Kuribara
Sekine, H., Nagao, S., Kuribara, H., et al. (1997): Behav-
ioral effects of N-cyanomethylmethamphetamine, a 
product from smoking methamphetamine with tobacco, 
in mice and rats. Pharmacol. Biochem. Behav. 57: 
167-172.
Sershen, H., Hashim, A., Harsing, L., et al. (1991): Chronic 
nicotine-induced changes in dopaminergic system: 
Effect of behavioral response to dopamine agonist. 
Pharmacol. Biochem. Behav. 39, 545-547.
Stevens, K.E., Meltzer, J. and Rose, G.M. (1995): Nicotinic 
cholinergic normalization of amphetamine-induced 
loss of auditory gating in freely moving rats. Psycho-
pharmacology 119, 163-170.
Stolerman, I.P., Fink, R. and Javik, M.E. (1973): Acute and 
chronic tolerance to nicotine measured by activity in 
rats. Psychopharmacologia (Berlin) 30, 329-342.
Tadokoro, S. and Kuribara, H. (1986): Reverse tolerance to 
the ambulation- increasing effect of methamphetamine 
in mice as an animal model of amphetamine psychosis. 
Psychopharmacol. Bull. 22, 757-762.
Van der Heuval, D.M.A. and Pasterkamp, R.J. (2008): Get-
ting connected in the dopamine system. Prog. Neuro-
biol. 85, 75-93.
Wise, R.A. and Bozarth, M.A. (1987): A psychomotor 
stimulant theory of addiction. Psychol. Rev. 94, 
469-492.









nicotineの併用によるMAPに対する増感現象の修飾を検討した。MAP（2 mg/kg s.c.）とnicotine（0.03, 0.1, 0.3および
1 mg/kg s.c.）の併用を3日間隔で5回反復投与すると、移所運動促進効果はnicotineの用量に依存して軽減された。しか
し、6回目にMAP（2 mg/kg s.c.）を単独投与してみると、nicotineの用量に関係なく、MAPに対する増感現象が誘発された。
MAPに対する増感を形成したマウスに対してMAP＋nicotineを併用投与すると、nicotineの用量に依存して、MAPの運
動促進作用が軽減された。一方、nicotine（1mg/kg s.c.）の反復投与は、MAPに対する感受性の変化を引き起こさなかった。
本実験結果は、nicotineはMAPの精神運動効果に対して抑制的に働くが、覚せい剤乱用による精神毒性の誘発を防止する
ことはなく、むしろ増強する可能性を示唆している。
（別刷請求先：栗原　久）
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